'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting

Clin Med (Lond). 2014 Aug;14(4):409-15. doi: 10.7861/clinmedicine.14-4-409.

Abstract

The use of novel psychoactive substances ('legal highs' or 'designer drugs') is increasing worldwide. Patients misusing such substances have been reported to experience severe or prolonged side effects requiring admission to acute or critical care wards. These complications can be life threatening if misdiagnosed or mismanaged. As physicians have traditionally had less involvement with the management of such patients compared with their colleagues in emergency departments an update in the management of such patients is indicated. Here we present a summary of the management of those novel substances with the potential for serious complications based on a review of current literature.

Keywords: Complications; designer drugs; legal highs; management; novel psychoactive substances.

Publication types

  • Review

MeSH terms

  • Alkaloids / adverse effects
  • Cannabinoid Receptor Agonists / adverse effects
  • Designer Drugs / adverse effects
  • Designer Drugs / poisoning*
  • Humans
  • Piperazine
  • Piperazines / adverse effects
  • Psychotropic Drugs / adverse effects
  • Psychotropic Drugs / poisoning*
  • Sodium Oxybate / adverse effects
  • Substance-Related Disorders / therapy*

Substances

  • Alkaloids
  • Cannabinoid Receptor Agonists
  • Designer Drugs
  • Piperazines
  • Psychotropic Drugs
  • Piperazine
  • cathinone
  • Sodium Oxybate